Rocket Pharmaceuticals, Inc. (RCKT)Healthcare | Biotechnology | Cranbury, United States | NasdaqGM
3.72 USD
-0.19
(-4.859%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.66 -0.06 (-0.060%) ⇩ (July 13, 2026, 7:29 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:47 a.m. EDT
The immediate outlook is sharply bullish, driven by a massive catalyst: the FDA approval of KRESLADI for a rare childhood immune disease. This regulatory win has shifted the narrative from survival to commercial potential, evidenced by the stock jumping over 10% premarket and the overwhelming options flow where traders are betting on a surge to $5 and beyond. The technicals confirm this momentum, with the price reclaiming key moving averages and showing strong relative strength against the broader market. However, the long-term investment case remains deeply flawed. The company is a classic biotech value trap; it has lost over 90% of its value over the last nine years, with the most recent annual performance seeing a catastrophic collapse of nearly 87%. Fundamentals are dire, characterized by negative earnings, negative free cash flow, and a lack of profitability. While the balance sheet currently holds enough cash to survive, the path to sustainable revenue is unproven, and the market has punished the stock repeatedly for failed expectations. The recent approval is a necessary step, but it does not yet guarantee the sustained, multi-year growth required to justify a premium valuation in a sector rife with competition. Until the company demonstrates consistent commercial traction and a clear route to profitability, the long-term risk profile remains extreme. |
| Model | MAE |
|---|---|
| MSTL_115 ✓ | 0.097957 |
| MSTL_79 | 0.105631 |
| AutoTheta | 0.106983 |
| MSTL_79_115 | 0.108936 |
| AutoETS | 0.120360 |
| AutoARIMA | 0.120360 |
| MSTL | 0.124231 |
Forecast horizon: 60 days | Selected: MSTL_115
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.365 |
| Excess Kurtosis | -0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.403 |
| Market Cap | 406,200,032 |
| Forward P/E | -3.16 |
| Beta | 0.45 |
| Website | https://www.rocketpharma.com |
As of July 11, 2026, 2:47 a.m. EDT: Speculators are overwhelmingly bullish, positioning heavy call volume and open interest at strikes significantly above the current price ($5.00 and $7.50), while put activity remains negligible. This indicates a strong expectation of a rapid price recovery driven by the recent FDA approval, despite elevated implied volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.28196716 |
| Address1 | 9 Cedarbrook Drive |
| All Time High | 77.8 |
| All Time Low | 2.19 |
| Ask | 4.21 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.5 - Buy |
| Average Daily Volume10 Day | 3,144,390 |
| Average Daily Volume3 Month | 2,585,926 |
| Average Volume | 2,585,926 |
| Average Volume10Days | 3,144,390 |
| Beta | 0.445 |
| Bid | 3.17 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 2.181 |
| City | Cranbury |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.72 |
| Current Ratio | 6.124 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.86 |
| Day Low | 3.62 |
| Debt To Equity | 10.403 |
| Display Name | Rocket Pharmaceuticals |
| Dividend Date | 1,515,110,400 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -202,456,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.416 |
| Enterprise Value | 286,584,992 |
| Eps Current Year | -0.74833 |
| Eps Forward | -1.178 |
| Eps Trailing Twelve Months | -1.87 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.2944 |
| Fifty Day Average Change | 0.42560005 |
| Fifty Day Average Change Percent | 0.12918894 |
| Fifty Two Week Change Percent | 28.196716 |
| Fifty Two Week High | 5.45 |
| Fifty Two Week High Change | -1.7299998 |
| Fifty Two Week High Change Percent | -0.31743115 |
| Fifty Two Week Low | 2.53 |
| Fifty Two Week Low Change | 1.19 |
| Fifty Two Week Low Change Percent | 0.47035575 |
| Fifty Two Week Range | 2.53 - 5.45 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,424,269,800,000 |
| Float Shares | 86,883,123 |
| Forward Eps | -1.178 |
| Forward P E | -3.1578948 |
| Free Cashflow | -98,859,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 202 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03103 |
| Held Percent Institutions | 0.89472 |
| Implied Shares Outstanding | 109,193,549 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,515,110,400 |
| Last Split Factor | 1:4 |
| Long Business Summary | Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. |
| Long Name | Rocket Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 406,200,032 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_427906624 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -209,383,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 426,946,776 |
| Number Of Analyst Opinions | 11 |
| Open | 3.83 |
| Operating Cashflow | -179,618,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 609 659 8001 |
| Post Market Change | -0.059999943 |
| Post Market Change Percent | -1.6129017 |
| Post Market Price | 3.66 |
| Post Market Time | 1,783,985,387 |
| Previous Close | 3.91 |
| Price Eps Current Year | -4.971069 |
| Price Hint | 4 |
| Price To Book | 1.7056396 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.901 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.46154 |
| Region | US |
| Regular Market Change | -0.19 |
| Regular Market Change Percent | -4.85934 |
| Regular Market Day High | 3.86 |
| Regular Market Day Low | 3.62 |
| Regular Market Day Range | 3.62 - 3.86 |
| Regular Market Open | 3.83 |
| Regular Market Previous Close | 3.91 |
| Regular Market Price | 3.72 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,719,506 |
| Return On Assets | -0.35137 |
| Return On Equity | -0.64408 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 109,193,549 |
| Shares Percent Shares Out | 0.1663 |
| Shares Short | 18,159,054 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 22,449,450 |
| Short Name | Rocket Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.2041 |
| Short Ratio | 5.79 |
| Source Interval | 15 |
| State | NJ |
| Symbol | RCKT |
| Target High Price | 16.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 9.38636 |
| Target Median Price | 10.0 |
| Total Cash | 144,379,008 |
| Total Cash Per Share | 1.322 |
| Total Debt | 24,764,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.574475 |
| Two Hundred Day Average Change | 0.14552498 |
| Two Hundred Day Average Change Percent | 0.040712267 |
| Type Disp | Equity |
| Volume | 1,719,506 |
| Website | https://www.rocketpharma.com |
| Zip | 8,512 |